| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yuriy Filts, Robert E Litman, Javier Martínez, Lourdes Anta, Dieter Naber, Christoph U Correl. Corrigendum to "Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study" [Schizophr. Res. 239 (2022) 83-91]. Schizophrenia research. vol 246. 2022-07-19. PMID:35853294. |
corrigendum to "long-term efficacy and safety of once-monthly risperidone ism® in the treatment of schizophrenia: results from a 12-month open-label extension study" [schizophr. |
2022-07-19 |
2023-08-14 |
Not clear |
| Miguel Angel Ramos-Méndez, Carlos Alfonso Tovilla-Zárate, Isela Esther Juárez-Rojop, Mario Villar-Soto, Alma Delia Genis-Mendoza, Thelma Beatriz González-Castro, María Lilia López-Narváez, José Jaime Martínez-Magaña, Rosa Giannina Castillo-Avila, Guillermo Efrén Villar-Juáre. Effect of risperidone on serum IL-6 levels in individuals with schizophrenia: a systematic review and meta-analysis. International journal of psychiatry in clinical practice. 2022-07-15. PMID:35839173. |
effect of risperidone on serum il-6 levels in individuals with schizophrenia: a systematic review and meta-analysis. |
2022-07-15 |
2023-08-14 |
Not clear |
| Miguel Angel Ramos-Méndez, Carlos Alfonso Tovilla-Zárate, Isela Esther Juárez-Rojop, Mario Villar-Soto, Alma Delia Genis-Mendoza, Thelma Beatriz González-Castro, María Lilia López-Narváez, José Jaime Martínez-Magaña, Rosa Giannina Castillo-Avila, Guillermo Efrén Villar-Juáre. Effect of risperidone on serum IL-6 levels in individuals with schizophrenia: a systematic review and meta-analysis. International journal of psychiatry in clinical practice. 2022-07-15. PMID:35839173. |
risperidone has been significant correlated with a direct effect of interleukin-6 (il-6) levels in patients with schizophrenia. |
2022-07-15 |
2023-08-14 |
Not clear |
| Atefeh Zandifar, Rahim Badrfam, Hossein Sanjari Moghaddam, Shahin Akhondzade. Efficacy of Spironolactone as an Adjunctive Therapy to Risperidone to Improve Symptoms of Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled, Clinical Trial. Iranian journal of psychiatry. vol 17. issue 1. 2022-04-28. PMID:35480128. |
efficacy of spironolactone as an adjunctive therapy to risperidone to improve symptoms of schizophrenia: a double-blind, randomized, placebo-controlled, clinical trial. |
2022-04-28 |
2023-08-13 |
Not clear |
| Mingzhe Zhao, Jingsong Ma, Mo Li, Wenli Zhu, Wei Zhou, Lu Shen, Hao Wu, Na Zhang, Shaochang Wu, Chunpeng Fu, Xianxi Li, Ke Yang, Tiancheng Tang, Ruoxi Shen, Lin He, Cong Huai, Shengying Qi. Different responses to risperidone treatment in Schizophrenia: a multicenter genome-wide association and whole exome sequencing joint study. Translational psychiatry. vol 12. issue 1. 2022-04-28. PMID:35484098. |
different responses to risperidone treatment in schizophrenia: a multicenter genome-wide association and whole exome sequencing joint study. |
2022-04-28 |
2023-08-13 |
Not clear |
| Mingzhe Zhao, Jingsong Ma, Mo Li, Wenli Zhu, Wei Zhou, Lu Shen, Hao Wu, Na Zhang, Shaochang Wu, Chunpeng Fu, Xianxi Li, Ke Yang, Tiancheng Tang, Ruoxi Shen, Lin He, Cong Huai, Shengying Qi. Different responses to risperidone treatment in Schizophrenia: a multicenter genome-wide association and whole exome sequencing joint study. Translational psychiatry. vol 12. issue 1. 2022-04-28. PMID:35484098. |
we performed a pharmacogenomic study of the treatment response to risperidone in patients with schizophrenia by using a snp microarray -based genome-wide association study (gwas) and whole exome sequencing (wes)-based gwas. |
2022-04-28 |
2023-08-13 |
Not clear |
| Keqiang Wang, Meihong Xiu, Xiuru Su, Fengchun Wu, Xiangyang Zhan. Association between Changes in Total Antioxidant Levels and Clinical Symptom Improvement in Patients with Antipsychotic-Naïve First-Episode Schizophrenia after 3 Months of Risperidone Monotherapy. Antioxidants (Basel, Switzerland). vol 11. issue 4. 2022-04-23. PMID:35453331. |
association between changes in total antioxidant levels and clinical symptom improvement in patients with antipsychotic-naïve first-episode schizophrenia after 3 months of risperidone monotherapy. |
2022-04-23 |
2023-08-13 |
Not clear |
| Eleni Karatza, Samit Ganguly, Chi D Hornik, William J Muller, Amira Al-Uzri, Laura James, Stephen J Balevic, Daniel Gonzale. External Evaluation of Risperidone Population Pharmacokinetic Models Using Opportunistic Pediatric Data. Frontiers in pharmacology. vol 13. 2022-04-04. PMID:35370711. |
risperidone is approved to treat schizophrenia in adolescents and autistic disorder and bipolar mania in children and adolescents. |
2022-04-04 |
2023-08-13 |
Not clear |
| R Taurines, S Fekete, A Preuss-Wiedenhoff, A Warnke, C Wewetzer, P Plener, R Burger, M Gerlach, M Romanos, K M Egbert. Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone. Journal of neural transmission (Vienna, Austria : 1996). 2022-03-18. PMID:35303169. |
therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone. |
2022-03-18 |
2023-08-13 |
Not clear |
| R Taurines, S Fekete, A Preuss-Wiedenhoff, A Warnke, C Wewetzer, P Plener, R Burger, M Gerlach, M Romanos, K M Egbert. Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone. Journal of neural transmission (Vienna, Austria : 1996). 2022-03-18. PMID:35303169. |
knowledge on dose-concentration relationships of risperidone treatment in children and adolescents with schizophrenia or other psychotic disorders is, however, scarce and no age-specific therapeutic ranges have been established yet. |
2022-03-18 |
2023-08-13 |
Not clear |
| Ho Teck Tan, Manu La. Socio-Cultural Factors Delaying Treatment in a Patient with Late-Onset Schizophrenia. Case reports in psychiatry. vol 2022. 2022-03-08. PMID:35256911. |
she was diagnosed with late-onset schizophrenia and her symptoms improved with risperidone. |
2022-03-08 |
2023-08-13 |
Not clear |
| Mahsa Motamed, Hanieh Karimi, Hossein Sanjari Moghaddam, Sina Taherzadeh Boroujeni, Zahra Sanatian, Alireza Hasanzadeh, Mohammad-Reza Khodaei Ardakani, Shahin Akhondzade. Risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. International clinical psychopharmacology. 2022-03-08. PMID:35258035. |
risperidone combination therapy with adalimumab for treatment of chronic schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. |
2022-03-08 |
2023-08-13 |
human |
| Itay Perlstein, Avia Merenlender Wagner, Roberto Gomeni, Michael Lamson, Eran Harary, Ofer Spiegelstein, Attila Kalmanczhelyi, Ryan Tiver, Pippa Loupe, Micha Levi, Anna Elgar. Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of Risperidone. Clinical pharmacology in drug development. 2022-03-04. PMID:35245409. |
tv-46000 is a long-acting subcutaneous antipsychotic that uses a novel copolymer drug delivery technology in combination with a well-characterized molecule, risperidone, that is in clinical development as a treatment for schizophrenia. |
2022-03-04 |
2023-08-13 |
Not clear |
| Stanislav V Ivanov, Anatoly B Smulevich, Evgeniya I Voronova, Kausar K Yakhin, Tangyul Z Beybalaeva, Alena A Kato. Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study). Frontiers in psychiatry. vol 12. 2022-02-10. PMID:35140638. |
cariprazine is found to be effective in the treatment of negative symptoms in schizophrenia comparing to second generation antipsychotic risperidone. |
2022-02-10 |
2023-08-13 |
Not clear |
| Zhe Lu, Yuyanan Zhang, Hao Yan, Yi Su, Liangkun Guo, Yundan Liao, Tianlan Lu, Hao Yu, Lifang Wang, Jun Li, Wenqiang Li, Yongfeng Yang, Xiao Xiao, Luxian Lv, Yunlong Tan, Dai Zhang, Weihua Yu. ATAD3B and SKIL polymorphisms associated with antipsychotic-induced QTc interval change in patients with schizophrenia: a genome-wide association study. Translational psychiatry. vol 12. issue 1. 2022-02-09. PMID:35136033. |
a total of 2040 patients with schizophrenia were randomly assigned to six groups (olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, and first-generation antipsychotics; first-generation antipsychotics including haloperidol or perphenazine were also assigned randomly) and received 6-week antipsychotic treatment. |
2022-02-09 |
2023-08-13 |
Not clear |
| Xiaoe Lang, Dongmei Wang, Dachun Chen, Meihong Xiu, Huixia Zhou, Li Wang, Bo Cao, Xiangyang Zhan. Association Between Hippocampal Subfields and Clinical Symptoms of First-Episode and Drug Naive Schizophrenia Patients During 12 Weeks of Risperidone Treatment. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2022-01-31. PMID:35099766. |
association between hippocampal subfields and clinical symptoms of first-episode and drug naive schizophrenia patients during 12 weeks of risperidone treatment. |
2022-01-31 |
2023-08-13 |
human |
| Xi-Yu Wang, Hung-Yu Chan, Ching-Hua Li. Time to Rehospitalization for Different Oral Risperidone Dosing Frequencies in Patients With Schizophrenia: A 17-Year Retrospective Cohort Study. Journal of clinical psychopharmacology. 2022-01-10. PMID:35001060. |
time to rehospitalization for different oral risperidone dosing frequencies in patients with schizophrenia: a 17-year retrospective cohort study. |
2022-01-10 |
2023-08-13 |
Not clear |
| Xi-Yu Wang, Hung-Yu Chan, Ching-Hua Li. Time to Rehospitalization for Different Oral Risperidone Dosing Frequencies in Patients With Schizophrenia: A 17-Year Retrospective Cohort Study. Journal of clinical psychopharmacology. 2022-01-10. PMID:35001060. |
this retrospective cohort study aimed at determining whether the daily administration pattern of risperidone influences time to rehospitalization in patients with schizophrenia. |
2022-01-10 |
2023-08-13 |
Not clear |
| Yuriy Filts, Robert E Litman, Javier Martínez, Lourdes Anta, Dieter Naber, Christoph U Correl. Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study. Schizophrenia research. vol 239. 2021-12-09. PMID:34847501. |
long-term efficacy and safety of once-monthly risperidone ism® in the treatment of schizophrenia: results from a 12-month open-label extension study. |
2021-12-09 |
2023-08-13 |
Not clear |
| Mehrnoosh Azimi Sanavi, Hamed Ghazvini, Mehryar Zargari, Hossein Ghalehnoei, Zahra Hosseini-Kha. Effects of clozapine and risperidone antipsychotic drugs on the expression of CACNA1C and behavioral changes in rat 'Ketamine model of schizophrenia. Neuroscience letters. 2021-12-06. PMID:34801642. |
effects of clozapine and risperidone antipsychotic drugs on the expression of cacna1c and behavioral changes in rat 'ketamine model of schizophrenia. |
2021-12-06 |
2023-08-13 |
rat |